Related references
Note: Only part of the references are listed.Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up
Roy Fleischmann et al.
RHEUMATOLOGY (2020)
Population Pharmacokinetics of Sarilumab in Patients with Rheumatoid Arthritis
Christine Xu et al.
CLINICAL PHARMACOKINETICS (2019)
Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis
Paul Emery et al.
RHEUMATOLOGY (2019)
Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
Spencer L. G. James et al.
LANCET (2018)
Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET study
Cem Gabay et al.
RMD OPEN (2018)
Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
2016 update of the EULAR recommendations for the management of early arthritis
Bernard Combe et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Effects of tocilizumab on neutrophil function and kinetics
Laurence S. C. Lok et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2017)
Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
Roy Fleischmann et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Cytokines in rheumatoid arthritis - shaping the immunological landscape
Iain B. McInnes et al.
NATURE REVIEWS RHEUMATOLOGY (2016)
Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY
Anita Boyapati et al.
ARTHRITIS RESEARCH & THERAPY (2016)
Rheumatoid arthritis: IL-6 inhibition in RAdeja vu all over again?
Eric M. Ruderman
NATURE REVIEWS RHEUMATOLOGY (2015)
Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate Results of a Phase III Study
Mark C. Genovese et al.
ARTHRITIS & RHEUMATOLOGY (2015)
AB0037 Evaluation of the binding kinetics and functional bioassay activity of sarilumab and tocilizumab to the human il-6 receptor (il-6r) alpha
A. Rafique et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
IL-6-Mediated Induction of Matrix Metalloproteinase-9 Is Modulated by JAK-Dependent IL-10 Expression in Macrophages
Poonam Kothari et al.
JOURNAL OF IMMUNOLOGY (2014)
Circulating Protein Fragments of Cartilage and Connective Tissue Degradation Are Diagnostic and Prognostic Markers of Rheumatoid Arthritis and Ankylosing Spondylitis
Anne C. Bay-Jensen et al.
PLOS ONE (2013)
Targeting Interleukin-6: All the Way to Treat Autoimmune and Inflammatory Diseases
Toshio Tanaka et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2012)
Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach
Leonid Gibiansky et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2012)
Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis
Ernest Choy
RHEUMATOLOGY (2012)
Population Pharmacokinetic Analysis of Tocilizumab in Patients With Rheumatoid Arthritis
Nicolas Frey et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor
Jean-Michel Dayer et al.
RHEUMATOLOGY (2010)
The role of Interleukin 6 in the pathophysiology of rheumatoid arthritis
Srinivasan Srirangan et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2010)
Share Paper
